Home

Sergey Suchkov
 
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors.
 
In 1980, Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia.
 
From 1985 through 1987, Dr Suchkov worked as a Post Doc Research Associate, Institute of Medical Enzymology; from 1987 through 1989, was a Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, Dr Suchkov was a head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow to resume studies in the area of eye immunology done earlier as a medical student. In 1989, Dr Suchkov trained at the Lab of Immunology, NEI, Bethesda, MD, USA,, NIH and Lab of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology. From 1995 through 2004, Dr Suchkov was a Chairman of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health.
 
In 1993-1996, Dr Suchkov was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
 
At present, Dr Sergey Suchkov, M, PhD, is Professor in Immunology, I.M. Sechenov First Moscow Medical University, Dean of the School for PPPM Management and First Vice-President of the University of World Politics & Law, and Chair and Director, Department of Preventive, Personalized and Translational Medicine, A.I.Evdokimov Moscow State Medical & Dental University to cover a lot of responsibilities including PPPM.
 
Dr Suchkov is an author of more than 500 publications and 10 patents. He is a member of:
-         New York Academy of Sciences, New York, USA;
-         EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
-         ARVO (American Association for Research in Vision and Ophthalmology);
-         ISER (International Society for Eye Research);
-         All-Union (from 1992 - Russian) Biochemical Society;
-         All-Union (from 1992 - Russian) Immunological Society.
 
Dr Suchkov is a Secretary General of the UCC (United Cultural Covention), Cambridge, UK.
 
Abstract: "PPPM as a new model of and thus a unique tool in a global reshuffling of national and international healthcare services"
 
The medicine is undergoing a paradigm shift to strive from the diagnosis and treatment for prediction and prevention. A new systems approach to disease to pay its crucial attention on the trend would result in a new branch in the healthcare services, namely, predictive, preventive and personalized medicine (PPPM).
To achieve the practical implementation of PPPM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biomarkers of hidden abnormalities long before the disease clinically manifests itself. This strategy would give a real opportunity to secure preventive measures whose personalization could have a significant influence on demographics!
 
Two key objectives of PPPM are:
(i) detection of subclinical abnormalities with a selection of suitable targets for the next step of PPPM protocol, i.e., drug-based prevention;
(ii) drug-based correction of the abnormalities detected under the heading of preventive measures.
 
PPPM is thus a medical model being tailored to the individual and dictates a construction of PPPM algorithms to diagnose, to predict, and to prevent in time!
 
The first discriminatory step illustrating the PPPM-oriented survey is estimating of the correlation strength between genetic polymorphism and risks of the disease, and subsequent construction of the groups at risks. Those goals can be solved by using of BioChip methodology (each disease has individual fingerprints). As a result, a patient becomes a data carrier, i.e., he/she knows about possible risks of a disease, and the physician can reasonably select of preventive protocol, proceeding from the assays made. Individuals, selected at the first stage, undergo the second phase of the survey, which uses a panel of phenotypic biopredictors.
 
Three examples to illustrate the topic: T1D, Atherosclerosis,, Fertility Prophylaxis and Cancer models. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment. Medical practitioners will be able to thus provide more tailored prevention and treatment programs for their patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of health care resources. Use of PPPM is categorized into predictive and preventive medicine and personalized treatment optimization. The latter refers to pharmacogenomics which aims to match the best available drug or dose to an individual’s genomic profile. Pharmacogenomics can help to inform a tailored dosage regimen allowing for an improved drug response, while managing the risk adverse reactions.
 
Implementation of PPPM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy men-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPPM to elicit the content of the new branch.
 
PPPM consists of a wide variety of tests and tools. The decision to utilize them or not is made at the micro level – depending on the type of intervention it could be ordered by administration of hospitals and infirmaries, laboratories or clinics, by doctors, and sometimes directly by individuals/patients! Each decision-maker values the impact of their decision to use PPPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. So, a lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPPM! What is a realistic timeline for the incorporation of PPPM into the practice? Patients and their relatives want interventions that work right now! But this raises many critical questions that must be answered before data from basic research can be routinely incorporated into the daily healthcare delivery.
 
For instance, students would say that the basic science they learn the first two years in, for instance, medical schools is very important to secure the impact of PPPM into the practice. A new model of education to reach the goal should be integrated throughout the education to secure the knowledge and understanding of the soul of PPPM. Especially, that top efficacy of customizing educational process provides additional and/or supplementary education, assisting the children to build their own pathway to learn and to know, whilst disclosing their own talents!
 
In this connection a non-canonical approach has been used to create a team of young researchers and clinicians which has been recognized as an International Research Team of Youngsters rooted from a variety of universities and given a roof under the aegis of EPMA, Brussels, EU, and ISPM, Tokyo, Japan. Outcome of this activity within cohorts of gifted mentees may be used in the educational process further, and the latter has been pre-selected by us as bricks for getting the results of the designing activities in:
● student- schoolchild pairs or ● postgraduate student-graduate student-schoolchild trios.
 
As a rule, successful medical school mentees finalized pre-university or college intensive courses of training are usually demonstrating the ability to pursue an area of study in depth. This could be basic science research, applied and clinical research.
The above-mentioned has pre-determining value, because under the disintegration of the world community expressed the competition in quality of the scientific intellect dramatically increases.
The same occurs in the areas of quality of all of three segments of the educational process, i.e.,
Pre-College (secondary school), University and Graduate to get PPPM model succeeded.
 
So, coordinated measures to optimize the progress should be well-focused on solving the accumulating problems in healthcare and the concomitant economic burden that societies across the globe are facing more and more.
 
The reason is predicting the future is not a new calling neither even a new challenge to ask merely for the God’s help! So, no needs for soaring in the heaven! Well, indeed, PPPM offers great and real promise for the future, and next generations will speak about the XXI century as a time, when healthcare services became predictive and preventive, and its outcomes – secured.